146 related articles for article (PubMed ID: 14565246)
1. Structural basis for topoisomerase I inhibition by nucleoside analogs.
Gmeiner WH; Yu S; Pon RT; Pourquier P; Pommier Y
Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):653-8. PubMed ID: 14565246
[TBL] [Abstract][Full Text] [Related]
2. Effects of gemcitabine and araC on in vitro DNA synthesis mediated by the human breast cell DNA synthesome.
Jiang HY; Hickey RJ; Abdel-Aziz W; Malkas LH
Cancer Chemother Pharmacol; 2000; 45(4):320-8. PubMed ID: 10755321
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine (2',2'-difluoro-2'-deoxycytidine), an antimetabolite that poisons topoisomerase I.
Pourquier P; Gioffre C; Kohlhagen G; Urasaki Y; Goldwasser F; Hertel LW; Yu S; Pon RT; Gmeiner WH; Pommier Y
Clin Cancer Res; 2002 Aug; 8(8):2499-504. PubMed ID: 12171875
[TBL] [Abstract][Full Text] [Related]
4. NMR structure of a gemcitabine-substituted model Okazaki fragment.
Konerding D; James TL; Trump E; Soto AM; Marky LA; Gmeiner WH
Biochemistry; 2002 Jan; 41(3):839-46. PubMed ID: 11790105
[TBL] [Abstract][Full Text] [Related]
5. Interaction between DNA Polymerase lambda and anticancer nucleoside analogs.
Garcia-Diaz M; Murray MS; Kunkel TA; Chou KM
J Biol Chem; 2010 May; 285(22):16874-9. PubMed ID: 20348107
[TBL] [Abstract][Full Text] [Related]
6. Incorporation of gemcitabine and cytarabine into DNA by DNA polymerase beta and ligase III/XRCC1.
Prakasha Gowda AS; Polizzi JM; Eckert KA; Spratt TE
Biochemistry; 2010 Jun; 49(23):4833-40. PubMed ID: 20459144
[TBL] [Abstract][Full Text] [Related]
7. Antimetabolite incorporation into DNA: structural and thermodynamic basis for anticancer activity.
Gmeiner WH
Biopolymers; 2002 Nov; 65(3):180-9. PubMed ID: 12228923
[TBL] [Abstract][Full Text] [Related]
8. Polymerization of the triphosphates of AraC, 2',2'-difluorodeoxycytidine (dFdC) and OSI-7836 (T-araC) by human DNA polymerase alpha and DNA primase.
Richardson KA; Vega TP; Richardson FC; Moore CL; Rohloff JC; Tomkinson B; Bendele RA; Kuchta RD
Biochem Pharmacol; 2004 Dec; 68(12):2337-46. PubMed ID: 15548380
[TBL] [Abstract][Full Text] [Related]
9. [Non-clinical studies of gemcitabine--the mode of action and antitumor activities].
Tsukagoshi S
Gan To Kagaku Ryoho; 1999 Feb; 26(3):393-400. PubMed ID: 10065109
[TBL] [Abstract][Full Text] [Related]
10. The stability of a model substrate for topoisomerase 1-mediated DNA religation depends on the presence of mismatched base pairs.
Gmeiner WH; Salsbury F; Olsen CM; Marky LA
J Nucleic Acids; 2011; 2011():631372. PubMed ID: 21904666
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic activity of 2',2'-difluorodeoxycytidine, 5-aza-2'-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene.
Beauséjour CM; Gagnon J; Primeau M; Momparler RL
Biochem Biophys Res Commun; 2002 May; 293(5):1478-84. PubMed ID: 12054682
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the induction of apoptosis in human leukemic cell lines by 2',2'-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside.
Bouffard DY; Momparler RL
Leuk Res; 1995 Nov; 19(11):849-56. PubMed ID: 8551802
[TBL] [Abstract][Full Text] [Related]
13. Induction of topoisomerase I cleavage complexes by 1-beta -D-arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells.
Pourquier P; Takebayashi Y; Urasaki Y; Gioffre C; Kohlhagen G; Pommier Y
Proc Natl Acad Sci U S A; 2000 Feb; 97(4):1885-90. PubMed ID: 10677551
[TBL] [Abstract][Full Text] [Related]
14. Nucleoside-catabolizing enzymes in mycoplasma-infected tumor cell cultures compromise the cytostatic activity of the anticancer drug gemcitabine.
Vande Voorde J; Sabuncuoğlu S; Noppen S; Hofer A; Ranjbarian F; Fieuws S; Balzarini J; Liekens S
J Biol Chem; 2014 May; 289(19):13054-65. PubMed ID: 24668817
[TBL] [Abstract][Full Text] [Related]
15. Action of 2',2'-difluorodeoxycytidine on DNA synthesis.
Huang P; Chubb S; Hertel LW; Grindey GB; Plunkett W
Cancer Res; 1991 Nov; 51(22):6110-7. PubMed ID: 1718594
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for polymerase η-promoted resistance to the anticancer nucleoside analog cytarabine.
Rechkoblit O; Choudhury JR; Buku A; Prakash L; Prakash S; Aggarwal AK
Sci Rep; 2018 Aug; 8(1):12702. PubMed ID: 30140014
[TBL] [Abstract][Full Text] [Related]
17. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
[TBL] [Abstract][Full Text] [Related]
18. Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs.
Galmarini CM; Warren G; Senanayake MT; Vinogradov SV
Int J Pharm; 2010 Aug; 395(1-2):281-9. PubMed ID: 20580798
[TBL] [Abstract][Full Text] [Related]
19. Entrapment of DNA topoisomerase-DNA complexes by nucleotide/nucleoside analogs.
Gmeiner WH
Cancer Drug Resist; 2019; 2(4):994-1001. PubMed ID: 31930190
[TBL] [Abstract][Full Text] [Related]
20. Cellular pharmacology of gemcitabine.
Mini E; Nobili S; Caciagli B; Landini I; Mazzei T
Ann Oncol; 2006 May; 17 Suppl 5():v7-12. PubMed ID: 16807468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
